| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 67028 |
Intravitreal injection of a pharmacologic agent |
24,994 |
18,025 |
$992K |
| 92134 |
|
39,917 |
30,289 |
$356K |
| J9035 |
Injection, bevacizumab, 10 mg |
20,390 |
12,217 |
$191K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
10,677 |
7,722 |
$169K |
| J2778 |
Injection, ranibizumab, 0.1 mg |
454 |
281 |
$52K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
2,042 |
1,521 |
$36K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,168 |
926 |
$27K |
| Q5128 |
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg |
505 |
175 |
$21K |
| 92250 |
|
1,196 |
960 |
$18K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
343 |
282 |
$14K |
| 92226 |
|
347 |
123 |
$13K |
| 99233 |
Prolong inpt eval add15 m |
193 |
106 |
$9K |
| 92201 |
|
443 |
265 |
$6K |
| J0178 |
Injection, aflibercept, 1 mg |
30 |
14 |
$5K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
451 |
405 |
$3K |
| 99223 |
Prolong inpt eval add15 m |
17 |
14 |
$1K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
46 |
41 |
$1K |